Curated News
By: NewsRamp Editorial Staff
February 10, 2026

VolitionRx Expands to Japan with Nu.Q® Discover Assay Distribution Deal

Discuss on Substack
Original Source

TLDR

  • VolitionRx gains a strategic advantage by appointing Medical & Biological Laboratories as a distributor in Japan, expanding its global reach to nearly 100 clients worldwide.
  • VolitionRx appointed Medical & Biological Laboratories as a non-exclusive distributor of its Nu.Q Discover assays in Japan, expanding access to its nucleosome-based biomarker tests for researchers.
  • This distribution agreement helps advance disease research and drug development in Japan, potentially leading to earlier detection and improved outcomes for patients with life-altering diseases.
  • VolitionRx's epigenetics technology now reaches Japan through a new distributor, adding to its growing network of nearly 100 global clients in pharmaceutical and diagnostic research.

Impact - Why it Matters

This expansion matters because it represents a significant step forward in making advanced epigenetic diagnostics more accessible globally, particularly in Japan's sophisticated healthcare market. Epigenetic testing represents the next frontier in precision medicine, offering earlier and more accurate detection of diseases like cancer and sepsis than traditional methods. By expanding to Japan—a country with one of the world's most advanced healthcare systems and significant pharmaceutical research infrastructure—VolitionRx is positioning its nucleosome-based biomarker assays to potentially accelerate drug development and improve patient outcomes. For patients, this could mean earlier cancer detection when treatments are most effective, and for researchers, it provides another tool to advance personalized medicine approaches. The growing adoption of these assays by nearly 100 clients worldwide suggests they're gaining traction in the scientific community, potentially leading to breakthroughs in how we diagnose and monitor serious diseases.

Summary

VolitionRx (NYSE American: VNRX), a multi-national epigenetics company, has significantly expanded its global reach by appointing Medical & Biological Laboratories Co. Ltd. as a non-exclusive distributor for its Nu.Q® Discover assays in Japan. This strategic partnership opens the Japanese market to Volition's innovative nucleosome-based biomarker assays, which are increasingly utilized by drug developers and researchers worldwide. The company's growing global collaborator network now serves close to 100 clients, including leading pharmaceutical and diagnostic companies that rely on these assays for critical disease research, drug development, and late-stage clinical trials. This expansion represents a major milestone in Volition's mission to make its advanced epigenetic technologies more accessible internationally.

Volition is dedicated to advancing the science of epigenetics with a focus on saving lives and improving outcomes through earlier disease detection and monitoring. The company develops simple, cost-effective blood tests designed to detect and monitor various diseases, including certain cancers and conditions associated with NETosis such as sepsis. With research and development activities centered in Belgium and additional operations in the U.S. and London, Volition's innovative approach has the potential to transform patient care by enabling earlier intervention and better treatment monitoring. The company's commitment to improving quality of life through advanced diagnostic solutions underscores the importance of this Japanese market expansion.

For those interested in learning more about this development, the full press release is available through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio that provides advanced wire-grade press release syndication and comprehensive corporate communications solutions. InvestorWire offers enhanced press release services, article syndication to over 5,000 outlets, and social media distribution through IBN's extensive network. This partnership announcement demonstrates how Volition continues to build strategic relationships that support its global growth objectives while advancing the field of epigenetic diagnostics.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Expands to Japan with Nu.Q® Discover Assay Distribution Deal

blockchain registration record for this content.